The Prevalence Survey of ALDH Gene Family in Patients With Peripheral Arterial Occlusive Disease or Acute Coronary Syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05078814

Enrollment

600

Registered

2021-10-15

Start date

2018-03-01

Completion date

2026-12-31

Last updated

2021-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Peripheral Artery Occlusive Disease

Keywords

Peripheral Artery Occlusive Disease or Acute Coronary Syndrome

Brief summary

Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome （ACS）remains lacking.

Interventions

OTHERObservational research

Observational research

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age≧20 y/o 2. Using ankle-brachial index (ABI)\< 0.9, angiography, vascular duplex, CAT scan or cardiologists'impression to confirm the diagnosis of PAOD 3. Clinical presentation of claudication 4. diagnosis of ACS

Exclusion criteria

* If the patient refuses to be included in this study

Design outcomes

Primary

Measure	Time frame
The incidence of MALE(major adverse limb events) in peripheral arterial disease and acute coronary disease.	2 years

Secondary

Measure	Time frame
The incidence of MACCE(major adverse cardiac and cerebrovascular events) in peripheral arterial disease and acute coronary disease.	2 years

Countries

Taiwan

Contacts

Primary ContactWei-Ting Chang

cmcvecho2@gmail.com+886-6-2812811

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026